Developer docs
API playgroundTry for free, no card

Search company profiles

Brii Biosciences

Full company profile

uuid0000pod

Namestring
Brii Biosciences
Legal namestring
腾盛博药医药技术(北京)有限公司 (Brii Biosciences Pharmaceutical Technology (Beijing) Co., Ltd.)
Websiteurl
briibio.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Brii Biosciences is a clinical-stage biopharmaceutical company founded in 2018 with a dual US-China operating model, headquartered in Durham, North Carolina with R&D and commercial operations in Beijing and Shanghai. The company is publicly listed on the Hong Kong Stock Exchange (ticker BRIBF, IPO July 2021) and has raised approximately $415 million across its founding financing and 2021 Series C round. Brii develops therapeutic candidates in two therapeutic areas: infectious diseases, anchored by a chronic hepatitis B functional cure program built on siRNA (BRII-835/Elebsiran, licensed from Vir Biotechnology), an HBV immunotherapeutic (BRII-179/VBI-2601, IP acquired from VBI Vaccines in December 2024), and a broadly neutralizing HBV monoclonal antibody (BRII-877/VIR-3434); and central nervous system disorders, including a long-acting therapy for postpartum depression and major depressive disorder (BRII-296).

The company's revenue model is hybrid: licensing royalties and milestone payments from out-licensing arrangements (e.g., soralimixin licensed to Joincare Group in Greater China in July 2025, and various co-development collaborations with Vir, VBI, WuXi Biologics, Qpex Biopharma, AN2 Therapeutics, and Artizan Biosciences), product sales of its one approved asset — amubarvimab/romlusevimab, the first COVID-19 neutralizing antibody combination approved by China's NMPA in December 2021 and commercially launched in July 2022 — and strategic distribution arrangements with Sinopharm and China Resources Pharmaceutical Commercial Group for China market access. The company operates a sales-led GTM leveraging state-controlled Chinese distributors rather than its own sales force, and engages global pharmaceutical partners for asset sourcing and co-development.

Customer concentration is anchored on a small number of strategic partners and government-linked distributors; with one approved product facing an evolving COVID therapeutics market and multiple pipeline assets still in Phase 2 trials, Brii is structurally a pre-commercialization company with cash runway of US$276.1 million as of December 2025 and FY2025 net loss reduced to RMB 224.1 million from RMB 512.4 million in 2024. Recent strategic emphasis has shifted toward portfolio rationalization (acquiring full BRII-179 IP, divesting Qpex equity, out-licensing non-core assets), AI-augmented drug discovery via the December 2025 OpenBench collaboration, and discovery capability buildout through new Shanghai wet lab operations.

Short descriptiontext

Brii Biosciences is a US-listed (HKEX) clinical-stage biopharmaceutical company developing therapeutic candidates for infectious diseases — primarily chronic hepatitis B, HIV, COVID-19, and multi-drug resistant bacterial infections — and central nervous system disorders, bringing in-licensed and acquired global assets into the China market through state-distribution partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infectious disease therapeutics, monoclonal antibody therapies, hepatitis B treatment, clinical stage biopharmaceuticals, CNS drug development
Industry3 codes
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAKAGAH
Tuberculosis & Mycobacterial Diseases
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Agreements
TypeLicensing Royalties
Description

Revenue primarily generated from licensing agreements for drug candidates in Greater China territory, including VIR-2218 from Vir Biotechnology and BRII-179 from VBI Vaccines

briibio.com
2Product Sales
TypeHardware Sales
Description

Revenue from commercialized products such as the amubarvimab/romlusevimab combination therapy for COVID-19 approved in China

briibio.com
3Strategic Partnerships
TypeLicensing Royalties
Description

Revenue generation through strategic out-licensing agreements such as the soralimixin agreement with Joincare Group in Greater China

briibio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Brii Biosciences is a multi-national biopharmaceutical company that develops, licenses, and commercializes innovative therapeutic candidates for infectious diseases (chronic hepatitis B, HIV, COVID-19), CNS disorders (postpartum depression, major depressive disorder), and multi-drug resistant bacterial infections, primarily for the Greater China market. The company functions as a bridge between global pharmaceutical innovation (via partnerships with Vir Biotechnology, VBI Vaccines, WuXi Biologics, Qpex Biopharma) and Chinese patients, leveraging its licensed platform technologies (siRNA ESC+, monoclonal antibodies, bispecific antibodies) and partnerships with Sinopharm and China Resources Pharmaceutical Commercial Group for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Strong cash position of US$276.1 million as of December 31, 2025
+1 more record
Product overview1 text field

Brii Biosciences is a multi-national biopharmaceutical company developing first-in-class and different-in-class treatments for infectious diseases and CNS diseases. The company operates a pipeline of therapeutic candidates including BRII-179 (VBI-2601), a novel HBV immunotherapeutic; BRII-835 (VIR-2218/Elebsiran), an siRNA therapeutic for chronic hepatitis B; BRII-196/BRII-198 (Amubarvimab/Romlusevimab), a COVID-19 neutralizing antibody combination; BRII-296 for postpartum depression; BRII-732 and BRII-778 for HIV; and antibiotics BRII-636, BRII-672, and BRII-693 developed with Qpex Biopharma. The company focuses on areas with high unmet medical needs, social stigmas, and limited treatment options, with operations in China and the United States.

Product and service10 records
1Amubarvimab/Romlusevimab (BRII-196/BRII-198)
CategoryTherapeutic Product - COVID-19 Neutralizing Antibody
Description

Non-competing SARS-CoV-2 neutralizing antibody combination therapy derived from convalescent COVID-19 patients. Engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-life for durable treatment effect. Received NMPA approval in China in December 2021 and included in China's COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) in March 2022.

2BRII-835 (VIR-2218 / Elebsiran)
CategoryTherapeutic Product - HBV siRNA
Description

Subcutaneously administered HBV-targeting siRNA (small interfering RNA) with potential to stimulate effective immune response and direct antiviral activity against HBV. First siRNA in clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity. Received CDE Breakthrough Therapy Designation from China's Center for Drug Evaluation.

3BRII-179 (VBI-2601)
CategoryTherapeutic Product - HBV Immunotherapeutic
Description

Novel recombinant protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI's prophylactic 3-antigen HBV vaccine candidate. Designed to target enhanced B-cell and T-cell immunity for chronic hepatitis B functional cure. Currently in Phase 2 ENSURE and BRII-179-002 studies.

4BRII-296
CategoryTherapeutic Product - CNS / Postpartum Depression
Description

Long-acting therapy in development for postpartum depression (PPD) and major depressive disorder (MDD) with potential to change the paradigm of patient care by helping avoid hospitalization and preserve mother-infant bonding.

5BRII-732
CategoryTherapeutic Product - HIV
Description

Therapeutic designed for once-weekly oral dosing for HIV-infected patients to improve quality of life. Currently subject to FDA clinical hold.

6BRII-778
CategoryTherapeutic Product - HIV
Description

Therapeutic designed for once-weekly oral dosing for HIV-infected patients.

7BRII-636 (OMNIvance)
CategoryTherapeutic Product - MDR Antibiotic
Description

Intravenous ultra-broad-spectrum beta-lactamase inhibitor for the treatment of extended spectrum beta-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae, developed with Qpex Biopharma.

8BRII-672 (ORAvance)
CategoryTherapeutic Product - MDR Antibiotic
Description

Oral ultra-broad-spectrum beta-lactamase inhibitor for treatment of MDR gram-negative bacterial infections, developed with Qpex Biopharma.

9BRII-693 (QPX-9003)
CategoryTherapeutic Product - MDR Antibiotic
Description

Next generation synthetic polymyxin for treatment of MDR infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii. Brii Biosciences acquired global exclusive rights from Qpex Biopharma in June 2023.

10BRII-877 (VIR-3434)
CategoryTherapeutic Product - HBV Monoclonal Antibody
Description

Broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen for which Brii Bio licensed exclusive rights in Greater China from Vir Biotechnology (option exercised July 2022). Received CDE Breakthrough Therapy Designation from China's Center for Drug Evaluation.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1China Resources Pharmaceutical Commercial Group
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-07-19
Description

Strategic partnership to advance commercialization of long-acting COVID-19 neutralizing antibody therapy amubarvimab/romlusevimab combination in China.

briibio.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-30
Description

Strategic partnership for commercialization of long-acting COVID-19 neutralizing antibody therapy amubarvimab/romlusevimab combination in China.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-03-11
Description

Brii Bio provided funding to support COVID-19 and coronavirus research led by Dr. David Ho at the Aaron Diamond AIDS Research Center and other Columbia laboratories. Unrestricted grant for creating novel collaboration frameworks.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-21
Description

Multi-product collaboration to develop and commercialize three antibiotic products in China for treatment of highly resistant gram-negative pathogens including carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

5Artizan Biosciences
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-11-21
Description

Collaboration to advance three projects from Artizan's product portfolio using their IgA-SEQ technology platform to identify pro-inflammatory and pathogenic bacteria in the gut.

briibio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-14
Description

Joint development of BRII-179 (VBI-2601), a novel HBV immunotherapeutic candidate for chronic hepatitis B infection. Brii Bio leads and funds the Phase 1b/2a clinical study in Greater China.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-12-10
Description

Exclusive discovery research collaboration for novel bispecific antibody immunotherapeutics. Brii Bio licensed WuXi's WuXiBody bispecific antibody platform for discovering, developing, and manufacturing bispecific antibodies in China.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-05-24
Description

Vir Biotechnology granted Brii Bio exclusive rights to develop and commercialize up to four infectious disease drug candidates in Greater China. The partnership includes VIR-2218 (BRII-835), an siRNA therapeutic for HBV, and other pipeline candidates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-05-24
Description

Digital health partnership to explore innovative approaches for clinical research optimization and commercialization, leveraging Alibaba's digital platform and medical AI capabilities to improve patient engagement and drug development efficiency.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NASDAQ/HKEX-listed Chinese biopharma licensing and developing innovative therapies for Greater China; same bridge-company strategy and comparable therapeutic focus areas including infectious disease and oncology.

TypeBroad incumbent
Description

Global biopharma with established neuroscience and infectious disease franchises; Rogers Luo previously led Roche's China oncology business. Broad incumbent with overlapping therapy area ambitions in China.

TypeBroad incumbent
Description

Major incumbent biopharmaceutical company with deep infectious disease (HIV, HBV, COVID) and antiviral portfolio. Multiple Brii Bio leaders (Rogers Luo, Lianhong Xu, Lijie Zhong) came from Gilead, signaling overlapping therapeutic strategy and culture.

TypeDirect peer
Description

Former co-developer of BRII-179 (VBI-2601) HBV immunotherapeutic; Brii Bio recently acquired full IP rights from VBI. Closely comparable in the HBV therapeutic vaccine space and pipeline stage.

TypeDirect peer
Description

Clinical-stage biopharma developing RNAi therapeutics for chronic hepatitis B; comparable mechanism (siRNA), target indication (HBV functional cure), and pipeline stage to Brii Bio's BRII-835 program.

TypeDirect peer
Description

Direct peer and counterparty licensor — both companies co-develop siRNA (elebsiran/VIR-2218) and broadly neutralizing mAb (VIR-3434/BRII-877) therapeutics for chronic hepatitis B. Identical scientific platforms, shared pipeline assets, and ongoing arbitration create direct comparability.

TypeDirect peer
Description

Hong Kong-listed Chinese biopharma using a similar 'bridge' model to in-license and develop global innovative therapies for the China market. Highly comparable business model, geography focus, and infectious disease/CNS pipeline profile.

TypeOthers
Description

Strategic platform partner providing the WuXiBody bispecific antibody discovery platform to Brii Bio. As a CRO/CDMO and platform provider, WuXi is an enabling peer rather than direct competitor but is closely tied to Brii Bio's discovery capabilities.

TypeRegional player
Description

Leading Chinese biopharmaceutical company developing innovative biologics including oncology and infectious disease therapeutics; comparable HKEX-listed Chinese biotech with similar innovative drug focus.

TypeBroad incumbent
Description

Global biopharma with strong HIV and infectious disease franchise. CEO Zhi Hong, CMO Li Yan, and SVP John Kraus came from GSK; comparable therapeutic areas (HIV, HBV, neuroscience) and talent pool overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brii Biosciences

Biopharmaceutical Therapeuticsbriibio.com

Brii Biosciences is a US-listed (HKEX) clinical-stage biopharmaceutical company developing therapeutic candidates for infectious diseases — primarily chronic hepatitis B, HIV, COVID-19, and multi-drug resistant bacterial infections — and central nervous system disorders, bringing in-licensed and acquired global assets into the China market through state-distribution partnerships.

What Brii Biosciences does

Brii Biosciences is a clinical-stage biopharmaceutical company founded in 2018 with a dual US-China operating model, headquartered in Durham, North Carolina with R&D and commercial operations in Beijing and Shanghai. The company is publicly listed on the Hong Kong Stock Exchange (ticker BRIBF, IPO July 2021) and has raised approximately $415 million across its founding financing and 2021 Series C round. Brii develops therapeutic candidates in two therapeutic areas: infectious diseases, anchored by a chronic hepatitis B functional cure program built on siRNA (BRII-835/Elebsiran, licensed from Vir Biotechnology), an HBV immunotherapeutic (BRII-179/VBI-2601, IP acquired from VBI Vaccines in December 2024), and a broadly neutralizing HBV monoclonal antibody (BRII-877/VIR-3434); and central nervous system disorders, including a long-acting therapy for postpartum depression and major depressive disorder (BRII-296).

The company's revenue model is hybrid: licensing royalties and milestone payments from out-licensing arrangements (e.g., soralimixin licensed to Joincare Group in Greater China in July 2025, and various co-development collaborations with Vir, VBI, WuXi Biologics, Qpex Biopharma, AN2 Therapeutics, and Artizan Biosciences), product sales of its one approved asset — amubarvimab/romlusevimab, the first COVID-19 neutralizing antibody combination approved by China's NMPA in December 2021 and commercially launched in July 2022 — and strategic distribution arrangements with Sinopharm and China Resources Pharmaceutical Commercial Group for China market access. The company operates a sales-led GTM leveraging state-controlled Chinese distributors rather than its own sales force, and engages global pharmaceutical partners for asset sourcing and co-development.

Customer concentration is anchored on a small number of strategic partners and government-linked distributors; with one approved product facing an evolving COVID therapeutics market and multiple pipeline assets still in Phase 2 trials, Brii is structurally a pre-commercialization company with cash runway of US$276.1 million as of December 2025 and FY2025 net loss reduced to RMB 224.1 million from RMB 512.4 million in 2024. Recent strategic emphasis has shifted toward portfolio rationalization (acquiring full BRII-179 IP, divesting Qpex equity, out-licensing non-core assets), AI-augmented drug discovery via the December 2025 OpenBench collaboration, and discovery capability buildout through new Shanghai wet lab operations.

Brii Biosciences firmographics

Firmographics
Name
Brii Biosciences
Legal name
腾盛博药医药技术(北京)有限公司 (Brii Biosciences Pharmaceutical Technology (Beijing) Co., Ltd.)
Website
https://briibio.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Brii Biosciences is a US-listed (HKEX) clinical-stage biopharmaceutical company developing therapeutic candidates for infectious diseases — primarily chronic hepatitis B, HIV, COVID-19, and multi-drug resistant bacterial infections — and central nervous system disorders, bringing in-licensed and acquired global assets into the China market through state-distribution partnerships.
Ownership category
akta.pro rank

Brii Biosciences industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAKAGAH
Tuberculosis & Mycobacterial Diseases
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Infectious disease therapeutics
  • Monoclonal antibody therapies
  • Hepatitis B treatment
  • Clinical stage biopharmaceuticals
  • CNS drug development

Where Brii Biosciences is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Brii Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Licensing Agreements: Revenue primarily generated from licensing agreements for drug candidates in Greater China territory, including VIR-2218 from Vir Biotechnology and BRII-179 from VBI Vaccines
  2. Product Sales: Revenue from commercialized products such as the amubarvimab/romlusevimab combination therapy for COVID-19 approved in China
  3. Strategic Partnerships: Revenue generation through strategic out-licensing agreements such as the soralimixin agreement with Joincare Group in Greater China

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Brii Biosciences product offering

Product offering

Core offering

Brii Biosciences is a multi-national biopharmaceutical company that develops, licenses, and commercializes innovative therapeutic candidates for infectious diseases (chronic hepatitis B, HIV, COVID-19), CNS disorders (postpartum depression, major depressive disorder), and multi-drug resistant bacterial infections, primarily for the Greater China market. The company functions as a bridge between global pharmaceutical innovation (via partnerships with Vir Biotechnology, VBI Vaccines, WuXi Biologics, Qpex Biopharma) and Chinese patients, leveraging its licensed platform technologies (siRNA ESC+, monoclonal antibodies, bispecific antibodies) and partnerships with Sinopharm and China Resources Pharmaceutical Commercial Group for commercialization.

Product overview

Brii Biosciences is a multi-national biopharmaceutical company developing first-in-class and different-in-class treatments for infectious diseases and CNS diseases. The company operates a pipeline of therapeutic candidates including BRII-179 (VBI-2601), a novel HBV immunotherapeutic; BRII-835 (VIR-2218/Elebsiran), an siRNA therapeutic for chronic hepatitis B; BRII-196/BRII-198 (Amubarvimab/Romlusevimab), a COVID-19 neutralizing antibody combination; BRII-296 for postpartum depression; BRII-732 and BRII-778 for HIV; and antibiotics BRII-636, BRII-672, and BRII-693 developed with Qpex Biopharma. The company focuses on areas with high unmet medical needs, social stigmas, and limited treatment options, with operations in China and the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Amubarvimab/Romlusevimab (BRII-196/BRII-198) Non-competing SARS-CoV-2 neutralizing antibody combination therapy derived from convalescent COVID-19 patients. Engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-life for durable treatment effect. Received NMPA approval in China in December 2021 and included in China's COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) in March 2022.
  • BRII-835 (VIR-2218 / Elebsiran) Subcutaneously administered HBV-targeting siRNA (small interfering RNA) with potential to stimulate effective immune response and direct antiviral activity against HBV. First siRNA in clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity. Received CDE Breakthrough Therapy Designation from China's Center for Drug Evaluation.
  • BRII-179 (VBI-2601) Novel recombinant protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI's prophylactic 3-antigen HBV vaccine candidate. Designed to target enhanced B-cell and T-cell immunity for chronic hepatitis B functional cure. Currently in Phase 2 ENSURE and BRII-179-002 studies.
  • BRII-296 Long-acting therapy in development for postpartum depression (PPD) and major depressive disorder (MDD) with potential to change the paradigm of patient care by helping avoid hospitalization and preserve mother-infant bonding.
  • BRII-732 Therapeutic designed for once-weekly oral dosing for HIV-infected patients to improve quality of life. Currently subject to FDA clinical hold.
  • BRII-778 Therapeutic designed for once-weekly oral dosing for HIV-infected patients.
  • BRII-636 (OMNIvance) Intravenous ultra-broad-spectrum beta-lactamase inhibitor for the treatment of extended spectrum beta-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae, developed with Qpex Biopharma.
  • BRII-672 (ORAvance) Oral ultra-broad-spectrum beta-lactamase inhibitor for treatment of MDR gram-negative bacterial infections, developed with Qpex Biopharma.
  • BRII-693 (QPX-9003) Next generation synthetic polymyxin for treatment of MDR infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii. Brii Biosciences acquired global exclusive rights from Qpex Biopharma in June 2023.
  • BRII-877 (VIR-3434) Broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen for which Brii Bio licensed exclusive rights in Greater China from Vir Biotechnology (option exercised July 2022). Received CDE Breakthrough Therapy Designation from China's Center for Drug Evaluation.

Quantifiable outcome

  • Strong cash position of US$276.1 million as of December 31, 2025
  • +1 more outcomes

Companies that use Brii Biosciences

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Brii Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Brii Biosciences partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • China Resources Pharmaceutical Commercial GroupcoreChannel Partner/ Reseller/ Distributor · 19 July 2021Strategic partnership to advance commercialization of long-acting COVID-19 neutralizing antibody therapy amubarvimab/romlusevimab combination in China.
  • SinopharmcoreChannel Partner/ Reseller/ Distributor · 30 March 2021Strategic partnership for commercialization of long-acting COVID-19 neutralizing antibody therapy amubarvimab/romlusevimab combination in China.
  • Columbia UniversityminorStrategic or Co-development Partner · 11 March 2020Brii Bio provided funding to support COVID-19 and coronavirus research led by Dr. David Ho at the Aaron Diamond AIDS Research Center and other Columbia laboratories. Unrestricted grant for creating novel collaboration frameworks.
  • Qpex BiopharmacoreStrategic or Co-development Partner · 21 November 2019Multi-product collaboration to develop and commercialize three antibiotic products in China for treatment of highly resistant gram-negative pathogens including carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
  • Artizan BiosciencesminorStrategic or Co-development Partner · 21 November 2019Collaboration to advance three projects from Artizan's product portfolio using their IgA-SEQ technology platform to identify pro-inflammatory and pathogenic bacteria in the gut.
  • VBI VaccinescoreStrategic or Co-development Partner · 14 November 2019Joint development of BRII-179 (VBI-2601), a novel HBV immunotherapeutic candidate for chronic hepatitis B infection. Brii Bio leads and funds the Phase 1b/2a clinical study in Greater China.
  • WuXi Biologics (药明生物)coreTechnology or Integration · 10 December 2018Exclusive discovery research collaboration for novel bispecific antibody immunotherapeutics. Brii Bio licensed WuXi's WuXiBody bispecific antibody platform for discovering, developing, and manufacturing bispecific antibodies in China.
  • Vir BiotechnologycoreStrategic or Co-development Partner · 24 May 2018Vir Biotechnology granted Brii Bio exclusive rights to develop and commercialize up to four infectious disease drug candidates in Greater China. The partnership includes VIR-2218 (BRII-835), an siRNA therapeutic for HBV, and other pipeline candidates.
  • Alibaba Health (阿里健康)coreStrategic or Co-development Partner · 24 May 2018Digital health partnership to explore innovative approaches for clinical research optimization and commercialization, leveraging Alibaba's digital platform and medical AI capabilities to improve patient engagement and drug development efficiency.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Brii Biosciences competitors and assessment

Company assessment

Direct peers

  • Zai Lab: NASDAQ/HKEX-listed Chinese biopharma licensing and developing innovative therapies for Greater China; same bridge-company strategy and comparable therapeutic focus areas including infectious disease and oncology.
  • VBI Vaccines: Former co-developer of BRII-179 (VBI-2601) HBV immunotherapeutic; Brii Bio recently acquired full IP rights from VBI. Closely comparable in the HBV therapeutic vaccine space and pipeline stage.
  • Arbutus Biopharma: Clinical-stage biopharma developing RNAi therapeutics for chronic hepatitis B; comparable mechanism (siRNA), target indication (HBV functional cure), and pipeline stage to Brii Bio's BRII-835 program.
  • Vir Biotechnology: Direct peer and counterparty licensor — both companies co-develop siRNA (elebsiran/VIR-2218) and broadly neutralizing mAb (VIR-3434/BRII-877) therapeutics for chronic hepatitis B. Identical scientific platforms, shared pipeline assets, and ongoing arbitration create direct comparability.
  • Everest Medicines: Hong Kong-listed Chinese biopharma using a similar 'bridge' model to in-license and develop global innovative therapies for the China market. Highly comparable business model, geography focus, and infectious disease/CNS pipeline profile.

Broad incumbents

  • Roche: Global biopharma with established neuroscience and infectious disease franchises; Rogers Luo previously led Roche's China oncology business. Broad incumbent with overlapping therapy area ambitions in China.
  • Gilead Sciences: Major incumbent biopharmaceutical company with deep infectious disease (HIV, HBV, COVID) and antiviral portfolio. Multiple Brii Bio leaders (Rogers Luo, Lianhong Xu, Lijie Zhong) came from Gilead, signaling overlapping therapeutic strategy and culture.
  • GlaxoSmithKline (GSK): Global biopharma with strong HIV and infectious disease franchise. CEO Zhi Hong, CMO Li Yan, and SVP John Kraus came from GSK; comparable therapeutic areas (HIV, HBV, neuroscience) and talent pool overlap.

Others

  • WuXi Biologics: Strategic platform partner providing the WuXiBody bispecific antibody discovery platform to Brii Bio. As a CRO/CDMO and platform provider, WuXi is an enabling peer rather than direct competitor but is closely tied to Brii Bio's discovery capabilities.

Regional players

  • Innovent Biologics: Leading Chinese biopharmaceutical company developing innovative biologics including oncology and infectious disease therapeutics; comparable HKEX-listed Chinese biotech with similar innovative drug focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Brii Biosciences social profiles

Digital presence

Brii Biosciences compliance and trust

Trust signal

Compliance1 record

Brii Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brii Biosciences leadership team

Management profile

Number of profiles

Profiles13 records

Brii Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brii Biosciences M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brii Biosciences

What does Brii Biosciences do?

Brii Biosciences is a multi-national biopharmaceutical company that develops, licenses, and commercializes innovative therapeutic candidates for infectious diseases (chronic hepatitis B, HIV, COVID-19), CNS disorders (postpartum depression, major depressive disorder), and multi-drug resistant bacterial infections, primarily for the Greater China market. The company functions as a bridge between global pharmaceutical innovation (via partnerships with Vir Biotechnology, VBI Vaccines, WuXi Biologics, Qpex Biopharma) and Chinese patients, leveraging its licensed platform technologies (siRNA ESC+, monoclonal antibodies, bispecific antibodies) and partnerships with Sinopharm and China Resources Pharmaceutical Commercial Group for commercialization.

Is Brii Biosciences a public or private company?

Brii Biosciences is a public company. It is classified as public and is currently operating.

When was Brii Biosciences founded?

Brii Biosciences was founded in 2018. It employs 51 to 100 people.

Where is Brii Biosciences based?

Brii Biosciences is headquartered in Durham, United States, in the North America region.

How does Brii Biosciences make money?

Three revenue lines are on record. Licensing Agreements are the primary driver. The others are product Sales and strategic Partnerships.

Who are Brii Biosciences's main competitors?

Direct peers on record are Zai Lab, VBI Vaccines, Arbutus Biopharma, Vir Biotechnology and Everest Medicines. Broad incumbents are Roche, Gilead Sciences and GlaxoSmithKline (GSK). WuXi Biologics is listed as an others. Innovent Biologics is listed as a regional player.

Does Brii Biosciences have an API?

No public API is recorded for Brii Biosciences.

What industry is Brii Biosciences in?

Brii Biosciences's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAKAGAH, Tuberculosis & Mycobacterial Diseases. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEEBrii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure ...Middle EastBrii Bio presented late-breaking data from its Phase 2 ENRICH and ENHANCE studies at AASLD 2026, supporting a BRII-179-based priming and enrichment strategy for HBV functional cure. The data across five Phase 2 studies, including ENSURE, ENRICH, and ENHANCE, support BRII-179's potential role in priming HBV-specific immune responses and improving cure rates with siRNA-based therapies.YahooBrii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional CureBrii Bio presented late-breaking data from its Phase 2 ENRICH and ENHANCE studies at AASLD 2026, showing BRII-179 priming improves HBsAg loss rates. In ENRICH, 41.9% achieved HBsAg loss at end of treatment and 32.4% maintained it at 24 weeks; in ENHANCE, triple therapy outperformed monotherapy. The data support further evaluation of BRII-179-based priming strategies.YahooBrii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional CureBrii Bio presented late-breaking data from its Phase 2 ENRICH and ENHANCE studies at AASLD 2026, showing BRII-179 priming improves HBsAg loss rates. In ENRICH, 41.9% achieved HBsAg loss at EOT and 32.4% at 24 weeks post-EOT; in ENHANCE, triple therapy outperformed monotherapy. The data support further evaluation of BRII-179-based priming strategies.TradingViewBrii Biosciences Limited Reports 32.4% HBsAg Loss at 24 Weeks in ENRICHBrii Biosciences reported Phase 2b ENRICH results showing 32.4% HBsAg loss retention at 24 weeks post-treatment, with 41.9% achieving loss at treatment end. ENHANCE Part A1 triple therapy showed 25.5% loss at treatment end versus 10.2% with PEG-IFNα monotherapy, but no statistical significance was provided.AInvestBrii Biosciences: Cash Discipline Buys Time, But the Binary Question RemainsBrii Biosciences extended its cash runway to 2029 by cutting R&D and administrative expenses, while reporting mixed clinical results for its hepatitis B candidate BRII-179 in Phase 2b trials. The company's development pipeline remains constrained by an ongoing arbitration with Vir Biotechnology over the licensing rights to elebsiran, which is required for the validated priming strategy.BioSpaceBrii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial ResultsBrii Biosciences reported its first-half 2026 financial results and provided corporate updates, including topline data from its HBV Phase 2b ENRICH and ENHANCE studies. The company held approximately US$260 million in cash as of June 30, 2026, and initiated clinical evaluation of its internally developed mRNA vaccine BRII-5395 for HCC.PR Newswire APACBrii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial ResultsBrii Biosciences reported its interim financial results for the first half of 2026, highlighting clinical data from Phase 2b studies supporting its HBV functional cure strategy and the initiation of clinical trials for its mRNA cancer vaccine, BRII-5395. The company maintains a cash position of approximately US$260 million while facing an ongoing arbitration with Vir Biotechnology that has paused the Phase 3 development of its candidate elebsiran. Additionally, the company disclosed a limited potential impact on clinical data due to a commercial assay kit recall by a central laboratory service provider.AInvestBrii Biosciences: HY other income RMB19.5 mlnNo content on the titled subject is present; the body is a stock-quote stub with only a date and time.MorningstarBrii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial ResultsBrii Biosciences reported its first-half 2026 financial results and clinical updates, including topline data from Phase 2b HBV studies. The company's cash position was approximately US$260 million as of June 30, 2026, and the first participant was dosed in a clinical study for BRII-5395, an mRNA vaccine for HCC.YahooBrii Bio reports end-of-treatment results for ENRICH and ENHANCE studiesBrii Bio reported end-of-treatment data from ENRICH and ENHANCE trials on BRII-179, elebsiran, and PEG-IFNα for chronic hepatitis B. The ENRICH priming regimen showed 42.9% HBsAg loss, while concurrent triple therapy yielded 25.5%. The company reached preliminary alignment with China's NMPA for a registrational trial.